Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-113M | $-104M | $-90M | -33.3% | - | -4.3% |
| 2024 | $0M | $-119M | $-109M | $-104M | -26.7% | - | -7.4% |
| 2023 | $0M | $-126M | $-118M | $-114M | -43.0% | - | 3.2% |
| 2022 | $0M | $-116M | $-114M | $-104M | -30.6% | - | - |
| 2021 | - | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Operating Expense | 122 |
| Research And Development | 90.43 |
| Selling General And Administration | 31.57 |
| Total Expenses | 122 |
| Operating Income | -122 |
| Total Operating Income As Reported | -122 |
| EBITDA | -112.80 |
| Normalized EBITDA | -112.80 |
| EBIT | -122 |
| Interest Income | 15.49 |
| Net Interest Income | 15.49 |
| Other Non Operating Income Expenses | 2.42 |
| Other Income Expense | 2.42 |
| Interest Income Non Operating | 15.49 |
| Net Non Operating Interest Income Expense | 15.49 |
| Pretax Income | -104.08 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -104.08 |
| Net Income From Continuing And Discontinued Operation | -104.08 |
| Net Income From Continuing Operation Net Minority Interest | -104.08 |
| Net Income | -104.08 |
| Net Income Common Stockholders | -104.08 |
| Net Income Including Noncontrolling Interests | -104.08 |
| Normalized Income | -104.08 |
| Diluted NI Availto Com Stockholders | -104.08 |
| Basic Average Shares | 73.99 |
| Diluted Average Shares | 73.99 |
| Reconciled Depreciation | 9.19 |
| General And Administrative Expense | 31.57 |
| Other Gand A | 31.57 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Nkarta, Inc.this co. | NKTX | $198M | - | 0.63 | -33.3% | - |
| Accendra Health, Inc. | ACH | $203M | -0.18 | -0.44 | 238.8% | 9.29 |
| Sanara MedTech Inc. | SMTI | $203M | -5.40 | 34.13 | -632.5% | 22.72 |
| TriSalus Life Sciences, Inc. | TLSI | $203M | -5.17 | -5.99 | 115.8% | -6.56 |
| Embecta Corp. | EMBC | $202M | 2.12 |
| - |
| - |
| -0.31 |
| -14.6% |
| 4.95 |
| Alector, Inc. | ALEC | $201M | - | 6.56 | -466.3% | - |
| Anika Therapeutics, Inc. | ANIK | $197M | -18.09 | 1.37 | -7.6% | -31.11 |
| Lucid Diagnostics Inc. | LUCD | $195M | - | 17.79 | -645.1% | - |
| Cartesian Therapeutics, Inc. | RNAC | $192M | -1.48 | -1.52 | 103.2% | -0.96 |
| Peer Median | - | -3.32 | 0.53 | -11.1% | 2.00 | |